SANDOZ WITHDRAWING PARLODEL POSTPARTUM LACTATION SUPPRESSION INDICATION
Executive Summary
SANDOZ WITHDRAWING PARLODEL POSTPARTUM LACTATION SUPPRESSION INDICATION five years after FDA first requested that the company voluntarily withdraw the indication. Sandoz announced Aug. 18 that it was taking the action "despite its confidence that the drug is safe and effective." Parlodel (bromocriptine) will remain on the market for treatment of Parkinson's disease, acromegaly and hyperprolactinemia-associated dysfunctions.